Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Samiran Panda and Balram Bhargava.
Samiran Panda
Connection Strength
6.885
Balram Bhargava
  1. Face mask - An essential armour in the fight of India against COVID-19. Indian J Med Res. 2021 Jan & Feb; 153(1 & 2):233-237.
    View in: PubMed
    Score: 0.922
  2. Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.243
  3. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.243
  4. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.243
  5. India's pragmatic vaccination strategy against COVID-19: a mathematical modelling-based analysis. BMJ Open. 2021 07 02; 11(7):e048874.
    View in: PubMed
    Score: 0.239
  6. Responsive and agile vaccination strategies against COVID-19 in India. Lancet Glob Health. 2021 09; 9(9):e1197-e1200.
    View in: PubMed
    Score: 0.238
  7. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 2021 Jun 01; 28(4).
    View in: PubMed
    Score: 0.237
  8. An Epidemiological Analysis of SARS-CoV-2 Genomic Sequences from Different Regions of India. Viruses. 2021 05 17; 13(5).
    View in: PubMed
    Score: 0.236
  9. SARS-CoV-2 re-infection: development of an epidemiological definition from India. Epidemiol Infect. 2021 03 26; 149:e82.
    View in: PubMed
    Score: 0.234
  10. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021 03 02; 12(1):1386.
    View in: PubMed
    Score: 0.233
  11. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 05; 21(5):637-646.
    View in: PubMed
    Score: 0.231
  12. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021 Feb 19; 24(2):102054.
    View in: PubMed
    Score: 0.231
  13. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian J Med Res. 2021 Jan & Feb; 153(1 & 2):93-114.
    View in: PubMed
    Score: 0.230
  14. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):120.
    View in: PubMed
    Score: 0.223
  15. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):122-123.
    View in: PubMed
    Score: 0.223
  16. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):117-118.
    View in: PubMed
    Score: 0.223
  17. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):138-140.
    View in: PubMed
    Score: 0.223
  18. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):141.
    View in: PubMed
    Score: 0.223
  19. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):135-136.
    View in: PubMed
    Score: 0.223
  20. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):144-145.
    View in: PubMed
    Score: 0.223
  21. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):128-129.
    View in: PubMed
    Score: 0.223
  22. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):125-126.
    View in: PubMed
    Score: 0.223
  23. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):147-148.
    View in: PubMed
    Score: 0.223
  24. Authors' response. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):132-133.
    View in: PubMed
    Score: 0.223
  25. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020 Jul & Aug; 152(1 & 2):48-60.
    View in: PubMed
    Score: 0.223
  26. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020 May; 151(5):459-467.
    View in: PubMed
    Score: 0.220
  27. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021. Int J Infect Dis. 2021 Jul; 108:145-155.
    View in: PubMed
    Score: 0.059
  28. Clinical profile of hospitalized COVID-19 patients in first & second wave of the pandemic: Insights from an Indian registry based observational study. Indian J Med Res. 2021 05; 153(5&6):619-628.
    View in: PubMed
    Score: 0.059
  29. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 07; 21(7):950-961.
    View in: PubMed
    Score: 0.058
  30. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021 03; 9(3):e257-e266.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.